BeiGene Presents Updated Head to Head Results from Phase 3

 Volver  Ver
BeiGene Presents Updated Head to Head Results from Phase 3
 PDF   10   06/2020
 Ver

BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

Rating

Rate this publication

Publicaciones relacionadas

ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (ASCO)
ASPEN: Results of a Phase 3 Randomized Trial of Zanubrutinib versus Ibrutinib for Patients with Waldenström Macroglobulinemia (ASCO)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild‑type Waldenström Macroglobulinemia poster
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild‑type Waldenström Macroglobulinemia poster
Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety
Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety
 Volver